Brief: Intra-Cellular Therapies Announces Positive Topline Results In Second Phase 3 Trial Testing Lumateperone As Adjunctive Depression Therapy

Intra-Cellular Therapies

18/06/2024 13:05

June 18 (Reuters) - Intra-Cellular Therapies Inc
 ITCI.O :
    * INTRA-CELLULAR THERAPIES ANNOUNCES POSITIVE TOPLINE
RESULTS IN
SECOND PHASE 3 TRIAL EVALUATING LUMATEPERONE AS ADJUNCTIVE
THERAPY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER
    * INTRA-CELLULAR THERAPIES INC: LUMATEPERONE 42 MG MET
PRIMARY
ENDPOINT
    * INTRA-CELLULAR THERAPIES INC: LUMATEPERONE 42 MG ALSO MET
KEY
SECONDARY ENDPOINT
    * INTRA-CELLULAR THERAPIES INC: SNDA SUBMISSION FOR
ADJUNCTIVE
TREATMENT OF MDD ANTICIPATED IN SECOND HALF

Source text for Eikon:  ID:nGNX97l4NW 
Further company coverage:  ITCI.O 

 ((Reuters.Briefs@thomsonreuters.com;))